Drugs / Aducanumab
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT05216887 | Feb → Jul 2022 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT04924140 | Jun → Oct 2021 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02782975 | May → Nov 2016 | Alzheimer disease | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02434718 | Jun 2015 → Dec 2016 | Alzheimer disease | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01677572 | Oct 2012 → Jul 2019 | Alzheimer disease | Biogen | Terminated | No outcome recorded |
| Phase 1 | NCT01397539 | Jun 2011 → Aug 2013 | Alzheimer disease | Biogen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03639987 | Dec 2018 → Jul 2019 | Alzheimer disease | Biogen | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05310071 | Jun 2022 → Aug 2024 | Alzheimer disease | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT04241068 | Mar 2020 → Jul 2024 | Alzheimer disease | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT02484547 | Sep 2015 → Aug 2019 | Alzheimer disease | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT02477800 | Aug 2015 → Aug 2019 | Alzheimer disease | Biogen | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05469009 Background | Jul 2022 → Jul 2029 expected | Alzheimer disease type 1, cognitive impairment with or without cerebellar ataxia | Ali Rezai | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05108922 Comparator | Nov 2021 → Sep 2022 | Alzheimer disease | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aducanumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05216887 ↗ |
| Known as | aducanumab-avwa | “A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic...” NCT05108922 ↗ |
| Known as | Aduhelm | ChEMBL registry synonym — accepted as the source's own label CHEMBL3039540 ↗ |
| Known as | BIIB037 | “Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103,...” NCT04241068 ↗6“Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease” NCT01677572 ↗ “Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease” NCT02434718 ↗ “221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease” NCT02477800 ↗ “221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease” NCT02484547 ↗ “Aducanumab (BIIB037)” NCT03639987 ↗ |
| Modality | Monoclonal antibody | “BIIB037 is a fully human immunoglobulin gamma 1 (IgG1) monoclonal antibody” NCT01397539 ↗ |
| Route | Intravenous | “single intravenous (IV) infusions” NCT01397539 ↗ |
| Target | APP | “Amyloid-beta A4 protein binding agent” CHEMBL3039540 ↗ |